Merck & Co Inc
NYSE: MRK
$99.60
+$0.15 (+0.2%)
Real Time Data Delayed 15 Min.
MRK Articles
Chevron, Verizon, Pfizer, and Merck combined to weigh on the DJIA Tuesday.
Published:
Last Updated:
Merck and Pfizer each saw their shares sink early on Monday after the firms gave an update on their type 2 diabetes treatment.
Published:
Last Updated:
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
Published:
Last Updated:
Merck saw its shares slip on Wednesday after the firm reported that it will be halting its mid-to-late-stage clinical trial for the treatment of Alzheimer’s disease.
Published:
Last Updated:
JPMorgan, Apple, Merck, and Goldman Sachs all set new 52-week highs and dominated the rising DJIA on Tuesday.
Published:
Last Updated:
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.
Published:
Last Updated:
Merck reported disappointing fourth-quarter financial results before the markets opened on Thursday.
Published:
Last Updated:
24/7 Wall St. has put together a preview of the two Dow stocks scheduled to report their quarterly results on Thursday: Merck and Visa.
Published:
Last Updated:
Five of the Dow stocks are reporting next week, and this has the potential to sustain the run that the index has made since the Trump rally began and push it even further beyond 20,000.
Published:
Last Updated:
The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly down.
Published:
Last Updated:
GE, Merck, Boeing, and Exxon Mobil lead the DJIA to a small loss on Monday.
Published:
Last Updated:
Merck, P&G, IBM, and Exxon Mobil lift DJIA by more than 75 points on Friday.
Published:
Last Updated:
Exxon Mobil, Merck, Goldman Sachs, and Pfizer sink the DJIA on Thursday.
Published:
Last Updated:
Oddly, perhaps, the best performing stock in the first two weeks of the year is drug maker Merck.
Published:
Last Updated:
The the attacks against drug pricing and competition do not seem to be going away, but somehow, Merck has managed to find itself as a top pick for pharmaceutical and biohealth analysts.
Published:
Last Updated: